Tags : IMP4297

Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297)

Shots: The two companies will co-develop and conduct clinical trials for senaparib across multiple cancer indications in China. Junshi to invest $43.4M in cash, representing 50% of the JV while Impact will supply senaparib in Mainland China, Hong Kong, and Macau representing the other 50% The JV will focus on the research, development & commercialization […]Read More